QuantX Biosciences and Pandorum Technologies each announced fresh capital raises this week, underscoring the biotech sector’s continued appetite for differentiated drug development approaches seeking to improve efficiency, scalability, and clinical impact across therapeutic areas.

QuantX closes $85 million Series B, with Sanofi as a co-lead investor

QuantX Biosciences closed an oversubscribed $85 million Series B financing co-led by LAV and Sanofi Ventures, with participation from Hongshan and existing investors.¹ The round brings QuantX’s total capital raised to $130 million since its founding in 2022.

The company is expecting to use the funding to advance its lead oral small-molecule programs, including a STAT6 inhibitor and an IL-17 inhibitor, both targeting immunology and inflammation indications.¹ Funding is also expected to be used to support continued discovery efforts across its computational platform.

“This fundraising is a watershed moment for QuantX as we continue to refine our strong discovery engine, add to our robust pipeline, and advance multiple programs towards human studies,” said Wei Li, PhD, interim chief executive officer of QuantX, in a press release. Li noted that the company has advanced multiple first-in-class candidates into IND-enabling studies within three years of the company’s launch.

QuantX was co-founded by Wayne Tang, PhD, and Yax Sun, PhD, and was previously incubated by OrbiMed and Creacion Ventures.¹ The company’s platform integrates physics-based and statistical modeling with high-performance computing to design and optimize oral small molecules, an approach intended to reduce iteration cycles in early drug discovery.

David Wang, MD, PhD, partner and senior managing director at OrbiMed, says the company’s speed and asset quality distinguishes it from peers. “The combination of QuantX’s ability to deliver best-in-class assets and the speed by which they’re able to advance these programs makes for a unique value proposition across a variety of therapeutic indications,” Wang said in the press release.

Sanofi Ventures’ role as a co-lead investor signals continued interest by large pharmaceutical companies in externally developed computational discovery platforms, particularly those advancing oral therapies for immunology.¹ While Sanofi did not disclose any strategic or option-based rights tied to the investment, its participation aligns with the company’s broader push to access early innovation through venture investing rather than in-licensing at later, higher-risk stages.

Pandorum raises $18 million to advance regenerative exosome therapies

In a separate financing round, Pandorum Technologies announced the close of an $18 million Series B financing to support the clinical development of its tunable, exosome-based regenerative therapies, including Kuragenx, while expanding manufacturing and operations across the United States, Japan, and the Middle East.

The funding was led by Protons Corporate, and included participation from Galentic Pharma, Ashish Kacholia, Noblevast Advisory and Avinya Fund, and the Burman Family.² Bandana Kankani, an advisor and investor in Pandorum, guided the transaction.

Pandorum’s platform combines biology, engineering, and computation to develop programmable exosome therapies designed to reprogram pathological tissue states such as inflammation and fibrosis.²

The company’s lead focus is on ocular surface diseases, including Stevens–Johnson Syndrome and Neurotrophic Keratitis, for which Kuragenx has received FDA Orphan Drug Designation.²

“This funding would enable us to translate breakthrough science into programmable, disease-modifying therapies,” said co-founder and CEO Tuhin Bhowmick, PhD, adding that the company aims to scale from single-tissue to multi-tissue repair applications. Co-founder Arun Chandru emphasized the global need for regenerative approaches, particularly in corneal blindness.

Pandorum is pursuing a distributed manufacturing strategy, including partnerships with AGC Biologics in Italy and Nucelion Therapeutics in India, as it prepares for broader clinical and geographic expansion.²

Sources

1. QuantX Biosciences Closes Oversubscribed $85M Series B Financing QuantX Biosciences February 9, 2026 https://www.globenewswire.com/news-release/2026/02/09/3234526/0/en/QuantX-Biosciences-Closes-Oversubscribed-85M-Series-B-Financing.html
2. Pandorum Technologies Raises US$18 Million in Series B to Advance Global Access to Programmable Tissue Regenerative Therapies Pandorum Technologies February 9, 2026 https://www.businesswire.com/news/home/20260207246124/en/Pandorum-Technologies-Raises-US%2418-Million-in-Series-B-to-Advance-Global-Access-to-Programmable-Tissue-Regenerative-Therapies